The Spanish biotech group Peaches Biotech is a company focused on the creation of drugs based on advanced therapies, especially with cytokines, stem cells or T-lymphocytes, which will allow patients to take advantage of new therapeutic options that are cost-effective and break with current models of medicines.
These are the company's main areas of research work:
PRS, Selective Rich Plasma
A process based on a patent developed by Peaches Biotech that generates a set of selective cytokines for various tissues, allogeneically, and that produces a regenerative and immunomodulatory effect on these tissues and their immune response.
This process results in a platform that has the potential to develop more than 20 different biological drugs.
opT cells
Process based on a Peaches Biotech license of the Harvard Medical School BIDMC patent for the treatment of pancreatic cancer, by education of autologous T lymphocytes, in co-culture with three-dimensional organoids generated with pancreatic tumor cells.
This cell therapy technology will be tested against other solid tumors leading to other treatments.
Dr. Juan Carlos de Gregorio - Founder and CEO. 2005 Innovation Award IESE-Vocento-Ernst&Young Degree in Pharmacy, specializing in pharmaceuticals. Former CEO of Puleva Biotech.
Dr. Juan Pedro Lapuente - Chief Scientific Officer of Peaches Biotech. Doctor in Medicine, Master in Molecular and Cellular Biology from the University of Zaragoza, Master in Transfusion and Advanced Cellular Medicine and Therapies from the University of Liège. Master in Sports Traumatology from the Catholic University of Murcia.
Dr. Manuel Hidalgo - Director of the Division of Hematology-Oncology at Weill Cornell Medicine, New York-Presbyterian. Currently, he is a research associate at Peaches Biotech.
Dr. Senthil Muthuswamy - Associate Professor, Department of Medicine, Harvard Medical School, Boston, Massachusetts. Director, Program in Cell Biology, Beth Israel Deaconess Medical Centre. Currently, he is a research associate at Peaches Biotech.
Investigation
- Autoimmune infections (preclinical)
- Pancreatic cancer (preclinical)
- Muscle regeneration (preclinical)
- Bone regeneration (preclinical)
- Tendon regeneration (preclinical)
- Neuropathic pain treatment (preclinical)
Our research work is focused on democratizing and providing patients with innovative drugs based on advanced therapies.
Public and private hospitals and treatment centers
LivingCells y Fundación PONS, colaboradores para la prestación de servicios de aceleración a las startups instaladas en su Bioincubadora
Peaches Biotech
Peaches Biotech recibe el Premio Innova Health 2023 al proyecto más innovador
Peaches Biotech
Peaches Biotech recibe el sello de Pyme Innovadora del Ministerio de Ciencia e Innovación
Peaches Biotech
La nueva terapia celular, al rescate de la reparación de tejidos
Peaches Biotech
Peaches negocia con la Agencia del Medicamento para poder comenzar ensayos clínicos
Peaches Biotech
Nueva era de terapias avanzadas basadas en el uso de los secretomas celulares
Peaches Biotech
Peaches Biotech recibe 598.000 euros del CDTI por su proyecto PRS de terapias avanzadas
Peaches Biotech
La UAM y Peaches han creado la primera Cátedra en Terapias Avanzadas basadas en secretomas celulares
Peaches Biotech
Ya conocen el lenguaje celular del sistema inmunitario
Peaches Biotech
Peaches investiga un nuevo enfoque del tratamiento inmunológico contra el cáncer de páncreas
Peaches Biotech
